Browse > Article
http://dx.doi.org/10.5352/JLS.2022.32.12.962

Preventive Effect of Poricoic Acid against Nonalcoholic Steatohepatitis  

Kim, Hae Ran (Division of Longevity and Biofunctional Medicine, School of Korean Medicine, Pusan National University)
Jung, Dae Young (Division of Longevity and Biofunctional Medicine, School of Korean Medicine, Pusan National University)
Kim, Say (Division of Longevity and Biofunctional Medicine, School of Korean Medicine, Pusan National University)
Jung, Myeong Ho (Division of Longevity and Biofunctional Medicine, School of Korean Medicine, Pusan National University)
Publication Information
Journal of Life Science / v.32, no.12, 2022 , pp. 962-970 More about this Journal
Abstract
Nonalcoholic steatohepatitis (NASH) is the progressive stage of nonalcoholic fatty liver disease (NAFLD) that highly increases the risk of cirrhosis and liver cancer, and there are few therapeutic options available in the clinic. Poricoic acid (PoA), a component of Poria cocos Wolf, has a wide range of pharmacological activities; however, little is known about its effects on NASH. The preventive effects of PoA on NASH were examined in vivo and in vitro by analyzing triglyceride synthesis, inflammation and fibrosis. In the high fat and methionine-choline deficient diet (HFMCD)-induced NASH mice, PoA reduced the liver weight and the levels of alanine aminotransferase and aspartate aminotransferase compared with non-treated HFMCD group. The staining with Oil Red O and hematoxylin and eosin revealed that PoA administration reduced red staining and the size of lipid droplet. qPCR analysis showed that PoA also reduced the expression of genes related to triglyceride synthesis. Further, immunostaining with CD68 and qPCR analysis revealed that PoA reduced the staining with CD68 and the expression of inflammatory genes induced by HFMCD. Moreover, PoA reduced the staining with sirius red and antibody of α-smooth muscle actin and also reduced the expression of genes related to fibrosis. The treatment of PoA to AML12 cells reduced the increase in triglyceride amount and expression of genes associated with triglyceride synthesis, inflammation and fibrosis. Taken together, our study indicate that PoA has therapeutic effect on NASH through preventing triglyceride synthesis, inflammation and fibrosis.
Keywords
Fibrosis; inflammation; nonalcoholic steatohepatitis (NASH); Poricoic acid; triglyceride synthesis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Sheka, A. C., Adeyi O., Thompson J., Hameed, B., Crawford, P. A. and Ikramuddin, S. 2020. Nonalcoholic Steatohepatitis. JAMA. 323, 1175-1183.   DOI
2 Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. and Sanyal, A. J. 2018. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908-922.   DOI
3 Ipsen, D. H., Lykkesfeldt, J. and Tveden-Nyborg, P. 2018. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell. Mol. Life Sci. 75, 3313-3327.   DOI
4 Kim, J. H., Sim, H. A., Jung, D. Y., Lim, E. Y., Kim, Y. T., Kim, B. J. and Jung, M. H. 2019. Poria cocus wolf extract ameliorates hepatic steatosis through regulation of lipid metabolism, inhibition of ER stress, and activation of autophagy via AMPK activation. Int. J. Mol. Sci. 20, 4801.   DOI
5 Li, Q., Ming, Y., Jia, H. and Wang, G. 2021. Poricoic acid A suppresses TGF-β1-induced renal fibrosis and proliferation via the PDGF-C, Smad3 and MAPK pathways. Exp. Ther. Med. 21, 289.   DOI
6 Chen, D. Q., Feng, Y. L., Chen, L., Liu, J. R., Wang, M., Vaziri, N. D. and Zhao, Y. Y. 2019. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis. Free Radic. Biol. Med. 134, 484-497.   DOI
7 Kikuchi, T., Uchiyama, E., Ukiya, M., Tabata, K., Kimura, Y., Suzuki, T. and Akihisa, T. 2011. Cytotoxic and apoptosis-inducing activities of triterpene acids from Poria cocos. J. Nat. Prod. 74, 137-144.   DOI
8 Nagappan, A., Jung, D. Y., Kim, J. H., Lee, H. and Jung, M. H. 2018. Gomisin N Alleviates ethanol-induced liver injury through ameliorating lipid metabolism and oxidative stress. Int. J. Mol. Sci. 19, 2601.   DOI
9 Rios, J. L. 2011. Chemical constituents and pharmacological properties of Poria cocos. Planta Med. 77, 681-691.   DOI
10 Schwabe, R. F., Tabas, I. and Pajvani, U. B. 2020. Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology 158, 1913-1928.   DOI
11 Zhang, C. and Yang, M. 2021. Current options and future directions for NAFLD and NASH treatment. Int. J. Mol. Sci. 22, 7571.   DOI
12 Nie, A., Chao, Y., Zhang, X., Jia, W., Zhou, Z. and Zhu, C. 2020. Phytochemistry and pharmacological activities of Wolfiporia cocos (F.A. Wolf) Ryvarden & Gilb. Front. Pharmacol. 11. 505249.   DOI
13 Powell, E. E., Wong, V. W. and Rinella, M. 2021. Non-alcoholic fatty liver disease. Lancet 397, 2212-2224.   DOI
14 Schuster, S., Cabrera, D., Arrese, M. and Feldstein, A. E. 2018. Triggering and resolution of inflammation in NASH. Nat. Rev. Gastroenterol. Hepatol. 15, 349-364.   DOI
15 Tanaka, N., Aoyama, T., Kimura, S. and Gonzalez, F. J. 2017. Targeting nuclear receptors for the treatment of fatty liver disease. Pharmacol. Ther. 179,142-157.   DOI